SilverCrest Metals
SILV
Collegium Pharmaceutical
COLL
Cars.com
CARS
Halozyme Therapeutics
HALO
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.46%440M | -5.63%436M | -2.31%465M | 2.12%1.83B | 1.11%457M | 5.04%438M | 7.44%462M | -4.03%476M | -6.36%1.8B | -4.84%452M |
Operating revenue | 0.46%440M | -5.63%436M | -2.31%465M | 2.12%1.83B | 1.11%457M | 5.04%438M | 7.44%462M | -4.03%476M | -6.36%1.8B | -4.84%452M |
Cost of revenue | -2.79%174M | -8.06%171M | 4.02%181M | 0.56%718M | -5.29%179M | 13.29%179M | 8.14%186M | -10.77%174M | -2.33%714M | 4.42%189M |
Gross profit | 2.70%266M | -3.99%265M | -5.96%284M | 3.15%1.12B | 5.70%278M | 0.00%259M | 6.98%276M | 0.33%302M | -8.85%1.08B | -10.54%263M |
Operating expense | -9.48%210M | -18.11%199M | 5.83%236M | -3.53%929M | -8.33%231M | -0.85%232M | -0.41%243M | -4.29%223M | 0.84%963M | 3.28%252M |
Selling and administrative expenses | -12.18%137M | -21.56%131M | 5.23%161M | -2.31%635M | -9.14%159M | 0.65%156M | 2.45%167M | -2.55%153M | 0.62%650M | 2.94%175M |
Research and development costs | -3.95%73M | -10.53%68M | 7.14%75M | -6.07%294M | -6.49%72M | -3.80%76M | -6.17%76M | -7.89%70M | 1.29%313M | 4.05%77M |
Operating profit | 107.41%56M | 100.00%66M | -39.24%48M | 57.63%186M | 327.27%47M | 8.00%27M | 135.71%33M | 16.18%79M | -48.92%118M | -78.00%11M |
Net non-operating interest income expense | -300.00%-4M | -600.00%-5M | -4M | 44.44%-5M | -400.00%-5M | 50.00%-1M | 150.00%1M | 0 | 55.00%-9M | 75.00%-1M |
Non-operating interest income | -57.14%3M | -75.00%2M | -42.86%4M | 66.67%25M | -50.00%3M | 75.00%7M | 166.67%8M | 250.00%7M | 150.00%15M | 200.00%6M |
Non-operating interest expense | -12.50%7M | 0.00%7M | 14.29%8M | 25.00%30M | 14.29%8M | 33.33%8M | 40.00%7M | 16.67%7M | -7.69%24M | 16.67%7M |
Other net income (expense) | 61.54%-5M | 40.00%-6M | 42.86%-12M | -52.38%-64M | -150.00%-20M | 0.00%-13M | 16.67%-10M | -133.33%-21M | -121.05%-42M | -100.00%-8M |
Gain on sale of security | ---- | 71.43%-2M | 50.00%-9M | -70.00%-51M | -200.00%-18M | 11.11%-8M | ---7M | -200.00%-18M | -275.00%-30M | -100.00%-6M |
Other non- operating income (expenses) | 0.00%-5M | -33.33%-4M | 0.00%-3M | -8.33%-13M | 0.00%-2M | -25.00%-5M | 75.00%-3M | 0.00%-3M | -9.09%-12M | -100.00%-2M |
Income before tax | 261.54%47M | 129.17%55M | -44.83%32M | 74.63%117M | 1,000.00%22M | 30.00%13M | 24M | 5.45%58M | -65.10%67M | -95.24%2M |
Income tax | 1,400.00%15M | 157.14%18M | -33.33%12M | 61.76%55M | 222.22%29M | -50.00%1M | 75.00%7M | -5.26%18M | -24.44%34M | 0.00%9M |
Net income | 166.67%32M | 117.65%37M | -50.00%20M | 87.88%62M | 0.00%-7M | 50.00%12M | 525.00%17M | 11.11%40M | -77.55%33M | -121.21%-7M |
Net income continuous Operations | 166.67%32M | 117.65%37M | -50.00%20M | 87.88%62M | 0.00%-7M | 50.00%12M | 525.00%17M | 11.11%40M | -77.55%33M | -121.21%-7M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 166.67%32M | 117.65%37M | -50.00%20M | 87.88%62M | 0.00%-7M | 50.00%12M | 525.00%17M | 11.11%40M | -77.55%33M | -121.21%-7M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 166.67%32M | 117.65%37M | -50.00%20M | 87.88%62M | 0.00%-7M | 50.00%12M | 525.00%17M | 11.11%40M | -77.55%33M | -121.21%-7M |
Basic earnings per share | 175.00%0.33 | 123.53%0.38 | -46.15%0.21 | 93.75%0.62 | 0.00%-0.07 | 50.00%0.12 | 525.00%0.17 | 14.71%0.39 | -76.30%0.32 | -122.58%-0.07 |
Diluted earnings per share | 175.00%0.33 | 123.53%0.38 | -48.72%0.2 | 96.77%0.61 | 0.00%-0.07 | 50.00%0.12 | 525.00%0.17 | 18.18%0.39 | -76.15%0.31 | -124.14%-0.07 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |